Juxta-glomerular cells serve as glomerular epithelial cell progenitors in glomerular disease

肾小球旁细胞在肾小球疾病中充当肾小球上皮细胞祖细胞

基本信息

  • 批准号:
    9816246
  • 负责人:
  • 金额:
    $ 62.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-08-05 至 2023-05-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY Chronic kidney disease (CKD) is increasing in the US, now impacting at least one in ten people. CKD typically results in end-stage kidney disease (ESRD), that requires either dialysis or kidney transplantation. Proteinuric glomerular diseases are the major cause of CKD and ESRD and are generally caused by progressive podocyte loss followed by glomerular scarring. Because podocytes are terminally differentiated epithelial cells they cannot regenerate. Therefore, following loss in disease, partial or complete podocyte replacement relies on trans-differentiation of adjacent progenitor cells. These include parietal epithelial cells, and cells of the renin lineage (CoRL), the latter being the focus of this competitive renewal. Unfortunately, endogenous podocyte replacement is often not robust enough to assure protection. Given this situation, and to address the unmet need to augment podocyte replacement through discovery of new targets, our long-term goal is to understand the mechanisms underlying podocyte regeneration, and identify therapeutic options towards restoring podocyte numbers and preventing glomerular scaring. We recently reported that CoRL are pluri-potent progenitors that can trans-differentiate towards podocytes, parietal epithelial cells, mesengial cells and pericytes. We have also shown that the transcription factor Wt1 is a critical player and is necessary for CoRL proliferation and migration, and its trans-differentiation to a podocyte fate. However, the precise molecular mechanism(s) underlying this CoRL biology are still poorly understood. To resolve this, the overall objective of this application is to investigate the mechanisms and pathways to augment CoRL progenitor function and its trans- differentiation into podocytes. Our central hypothesis is that we can ramp up the ability of these CoRL to become podocytes, and replace those lost by modulating distinct signaling systems such as Wnt signaling. To test this, we will pursue two Specific Aims: (1) Test the hypothesis that the progenitor capacity of cells of renin lineage (CoRL) to trans-differentiate to a podocyte fate is governed by the balance of WT1 and Wnt signaling, and (2) Identify pathways underlying the pluripotency of cells of renin lineage towards different adult kidney cell type fates in glomerular diseases. The approach is innovative as it is based on a unique ability to culture CoRL ex vivo, innovative bioengineered cell culture devices, a newly developed dual-reporter mice to definitively trace CoRL-podocyte trans-differentiation, and Quality-by-Design (QbD)-based methodologies to identify complex and robust culture conditions. The research is significant as it provides an in depth understanding of the potential of CoRL to differentiate into multiple kidney cell types even in adults. In addition, it will advance the field by identifying potentially novel therapeutic options towards restoring podocyte numbers, and in doing so, preventing and even reversing glomerular scaring in proteinuric glomerular diseases.
项目总结 慢性肾脏疾病(CKD)在美国正在增加,目前至少有十分之一的人受到影响。CKD通常 导致终末期肾病(ESRD),需要透析或肾移植。蛋白尿酸 肾小球疾病是慢性肾脏病和终末期肾病的主要原因,通常由进行性肾小球疾病引起 足细胞丢失,肾小球瘢痕形成。因为足细胞是终末分化的上皮细胞 它们不能再生。因此,在疾病丧失后,部分或全部足细胞替换依赖于 关于相邻祖细胞的转分化。这些细胞包括壁上皮细胞和肾素细胞。 血统(科尔),后者是这次竞争更新的焦点。不幸的是,内源性足细胞 替代往往不够坚固,不足以确保保护。在这种情况下,并解决未满足的问题 需要通过发现新的靶点来增加足细胞的替换,我们的长期目标是了解 足细胞再生的潜在机制,并确定修复足细胞的治疗方案 数字和防止肾小球惊吓。我们最近报道COIL是多能祖细胞, 可以向足细胞、壁上皮细胞、系膜细胞和周细胞跨向分化。我们还有 研究表明,转录因子Wt1是COIL增殖和生长所必需的关键因子。 迁徙及其转分化为足细胞的命运。然而,精确的分子机制(S) 在这种情况下,科尔的生物学仍然知之甚少。为了解决这个问题,本应用程序的总体目标是 目的是探讨增强COIL祖细胞功能及其反式作用的机制和途径。 分化为足细胞。我们的中心假设是,我们可以增强这些细胞的能力 成为足细胞,并通过调制不同的信号系统(如WNT信号)来取代丢失的足细胞。至 检验这一点,我们将追求两个具体目标:(1)检验肾素祖细胞能力的假说 转分化为足细胞命运的谱系(COIL)受WT1和Wnt信号平衡的控制, 以及(2)确定肾素谱系细胞对不同成人肾脏细胞的多能性的潜在途径 肾小球疾病的分型命运。这种方法是创新的,因为它基于培养Corl的独特能力 体外,创新的生物工程细胞培养设备,新开发的双报告小鼠最终确定 跟踪足细胞转分化和基于设计质量(QBD)的方法,以确定 复杂而稳健的培养条件。这项研究具有重要意义,因为它提供了对 COIL分化为多种肾细胞类型的潜力,即使在成人。此外,它还将推进 通过确定潜在的新的治疗方案来恢复足细胞数量,并在 因此,预防甚至逆转蛋白尿性肾小球疾病的肾小球瘢痕。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stuart James Shankland其他文献

Stuart James Shankland的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stuart James Shankland', 18)}}的其他基金

The Intersection of Podocyte Disease and Aging
足细胞疾病与衰老的交叉点
  • 批准号:
    10733868
  • 财政年份:
    2023
  • 资助金额:
    $ 62.07万
  • 项目类别:
Targeting Podocyte-Endothelial Cell Crosstalk as a FSGS Therapy
靶向足细胞-内皮细胞串扰作为 FSGS 疗法
  • 批准号:
    10635547
  • 财政年份:
    2023
  • 资助金额:
    $ 62.07万
  • 项目类别:
Autocrine and paracrine podocyte signals decrease glomerular function/health in aged kidneys
自分泌和旁分泌足细胞信号会降低老年肾脏的肾小球功能/健康
  • 批准号:
    10698100
  • 财政年份:
    2022
  • 资助金额:
    $ 62.07万
  • 项目类别:
Kidney Aging Impairs Progenitor and Endocrine Function
肾脏老化损害祖细胞和内分泌功能
  • 批准号:
    10549835
  • 财政年份:
    2020
  • 资助金额:
    $ 62.07万
  • 项目类别:
Kidney Aging Impairs Progenitor and Endocrine Function
肾脏老化损害祖细胞和内分泌功能
  • 批准号:
    10341118
  • 财政年份:
    2020
  • 资助金额:
    $ 62.07万
  • 项目类别:
Cell specific delivery of novel therapies to enhance glomerular regeneration and repair
细胞特异性递送新疗法以增强肾小球再生和修复
  • 批准号:
    10675681
  • 财政年份:
    2020
  • 资助金额:
    $ 62.07万
  • 项目类别:
Cell specific delivery of novel therapies to enhance glomerular regeneration and repair
细胞特异性递送新疗法以增强肾小球再生和修复
  • 批准号:
    10247521
  • 财政年份:
    2020
  • 资助金额:
    $ 62.07万
  • 项目类别:
Cell specific delivery of novel therapies to enhance glomerular regeneration and repair
细胞特异性递送新疗法以增强肾小球再生和修复
  • 批准号:
    10414816
  • 财政年份:
    2020
  • 资助金额:
    $ 62.07万
  • 项目类别:
Reduced Glomerular Progenitors Impair Regeneration in Aged Kidney
肾小球祖细胞减少会损害衰老肾脏的再生
  • 批准号:
    9329346
  • 财政年份:
    2016
  • 资助金额:
    $ 62.07万
  • 项目类别:
Rebuilding the glomerular filtration barrier by regenerating adult podocytes
通过再生成年足细胞重建肾小球滤过屏障
  • 批准号:
    9564892
  • 财政年份:
    2015
  • 资助金额:
    $ 62.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了